Kadcyla, a breast cancer drug marketed by Roche Products Limited that can give patients an extra six months of life has been turned down by the NHS drugs rationing body as it is too expensive.
Sir Andrew Dillon, chief executive of The National Institute for Health and Care Excellence (Nice) says “We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.” The manufacturer…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
